Collegium Pharmaceutical shares are trading higher after HC Wainwright & Co upgraded the stock from Neutral to Buy announced a price target of $47.
Portfolio Pulse from Benzinga Newsdesk
Collegium Pharmaceutical shares are trading higher after HC Wainwright & Co upgraded the stock from Neutral to Buy and announced a price target of $47.
July 30, 2024 | 3:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Collegium Pharmaceutical shares are trading higher following an upgrade from HC Wainwright & Co from Neutral to Buy, with a new price target of $47.
The upgrade from HC Wainwright & Co to Buy and the new price target of $47 is a strong positive signal for investors, likely driving short-term price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100